OrbiMed’s Arcutis Biotherapeutics ARQT Stock Holding History

OrbiMed’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,914,479	Closed	-$10.2M	–	115
2023 Q3	$10.2M	Hold	1,914,479	–	–	0.22%	84
2023 Q2	$18.2M	Hold	1,914,479	–	–	0.33%	72
2023 Q1	$21.1M	Sell	1,914,479 -545,629	-22%	-$7.89M	0.41%	64
2022 Q4	$36.4M	Sell	2,460,108 -339,892	-12%	-$5.94M	0.7%	52
2022 Q3	$53.5K	Sell	2,800,000 -1,981,646	-41%	-$44.9M	0.99%	36
2022 Q2	$102K	Sell	4,781,646 -1,292,204	-21%	-$26.5M	1.85%	19
2022 Q1	$117M	Hold	6,073,850	–	–	1.9%	18
2021 Q4	$126M	Hold	6,073,850	–	–	1.62%	20
2021 Q3	$145M	Hold	6,073,850	–	–	1.59%	19
2021 Q2	$166M	Hold	6,073,850	–	–	1.68%	16
2021 Q1	$176M	Hold	6,073,850	–	–	1.64%	17
2020 Q4	$171M	Buy	6,073,850 +1,400,000	+30%	+$34.3M	1.5%	17
2020 Q3	$137M	Hold	4,673,850	–	–	1.72%	17
2020 Q2	$141M	Hold	4,673,850	–	–	1.99%	19
2020 Q1	$139M	Buy	+4,673,850	New	+$126M	2.34%	12

Other funds holding ARQT

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

OrbiMed's ARQT Position: Q4 2023 in Review

OrbiMed sold out of Arcutis Biotherapeutics (ARQT) in Q4 2023, closing a stake of 1,914,479 shares — an estimated $10.2M sold.

OrbiMed first reported a position in ARQT in Q1 2020 and held it in 15 quarters. The position peaked at $176M in Q1 2021. 133 funds tracked by Wall St. Rank hold ARQT as of Q4 2023.

OrbiMed reported no remaining Arcutis Biotherapeutics position as of Q4 2023 after selling out during the quarter.
OrbiMed sold 1,914,479 Arcutis Biotherapeutics shares in Q4 2023, an estimated $10.2M.
OrbiMed first reported a position in Arcutis Biotherapeutics in Q1 2020 and held it in 15 quarters.
OrbiMed's Arcutis Biotherapeutics position peaked at $176M in Q1 2021.
133 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2023.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.